
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals is a specialty pharmaceutical company with a strong portfolio of rare disease products and a promising pipeline of late-stage candidates. The company has a history of successful drug launches and a targeted approach to strategic acquisitions, positioning them for continued growth and potential outperformance in the pharmaceutical market. Additionally, management's execution to date and their stated long-term goals suggest potential for strong financial performance and value creation for shareholders.
Bears say
Eton Pharmaceuticals is set to experience growth with their exclusive rights to market the FDA-approved oral therapy for leishmaniasis, with a projected $200M annual revenue by 2027. Their current revenue base of $8M and a discounted net present value of $1.58B supports a buy rating and 12-month price target of $57.00 per diluted share. Risks may arise in the areas of clinical, commercial, collaboration, dilution, legal and intellectual property, and competition.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares